Блокатор рецепторов к ангиотензину II олмесартан в прерывании сердечно-сосудистого континуума: сосудо - и кардиопротективные,антиатеросклеротические и метаболические плейотропные эффекты (часть 2)

Обложка

Цитировать

Полный текст

Аннотация

В статье представлен обзор плейотропной активности и клинической эффективности одного из представителей класса блокаторов рецепторов к ангиотензину II - олмесартана медоксомила. Проанализирован широкий спектр установленных в экспериментальных и клинических исследованиях вазо -, кардиопротективных, антиатерогенных, противовоспалительных и других эффектов олмесартана медоксомила. Приведены клинические исследования, изучающие антиатеросклеротическое воздействие данного препарата.

Об авторах

Марина Геннадьевна Бубнова

ФГБУ Государственный научно-исследовательский центр профилактической медицины Минздрава России

Email: mbubnova@gnicpm.ru
д-р мед. наук, проф., рук. отд. реабилитации и вторичной профилактики сочетанной патологии с лабораторией профилактики атеросклероза и тромбоза ФГБУ ГНИЦ ПМ 101000, Россия, Москва, Петроверигский пер., д. 10, стр. 3

Список литературы

  1. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991; 121 (4 Pt1): 1244-63.
  2. Mulvany M.J, Aalkjaer C. Structure and function of small arteries. Physiol Rev 1990; 70: 921-71.
  3. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982; 62: 347-504.
  4. Heagerty A.M, Aalkjaer C, Bund S.J et al. Small artery structure in hypertension. Dual processes of remodeling and growth. Hypertension 1993; 21: 391-7.
  5. Park J.B, Schiffrin E.L. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens 2001; 19: 921-30.
  6. Rizzoni D, Porteri E, Boari G.E et al. Prognostic significance of small artery structure in hypertension. Circulation 2003; 108: 2230-5.
  7. De Ciuceis C, Porteri E, Rizzoni D et al. Structural alterations of subcutaneous small - resistance arteries may predict major cardiovascular events in patients with hypertension. Am J Hypertens 2007; 20 (8): 46-52.
  8. Rizzoni D, Palombo C, Porteri E et al. Relationships between coronary flow vasodilator capacity and small artery remodeling in hypertensive patients. J Hypertens 2003; 21: 625-31.
  9. Rizzoni D, Porteri E, Castellano M et al. Vascular hypertrophy and remodeling in secondary hypertension. Hypertension 1996; 28: 785-90.
  10. Rizzoni D, Porteri E, Guefi D et al. Cellular hypertrophy in subcutaneous small arteries of patients with renovascular hypertension. Hypertension 2000; 35: 931-5.
  11. Muiesan M.L, Rizzoni D, Salvetti M et al. Structural changes in small resistance arteries and left ventricular geometry in patients with primary and secondary hypertension. J Hypertens 2002; 20: 1439-44.
  12. Li J.J, Chen J.L. Inflammation may be a bridge connecting hypertension and atherosclerosis. Med Hypotheses 2005; 64 (5): 925-9.
  13. Rosenfeld M.E. An overview of the evolution of the atherosclerotic plaque: from fatty streak to plaque rupture and thrombosis. Z Kardiol 2000; 89 (Suppl. 7): 2-6.
  14. Matsushita M, Nishikimi N, Sakurai T, Nimura Y. Relationship between aortic calcification and atherosclerotic disease in patients with abdominal aortic aneurysm. Int Angiol 2000; 19 (3): 276-9.
  15. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340 (2): 115-26.
  16. Kramer C.M, Anderson J.D. MRI of atherosclerosis: diagnosis and monitoring therapy. Expert Rev Cardiovasc Ther 2007; 5 (1): 69-80.
  17. Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation 1998; 97 (12): 1195-206.
  18. Wasserman B.A. Clinical carotid atherosclerosis. Neuroimaging Clin N Am 2002; 12 (3): 403-19.
  19. Rizzoni D, Muiesan M.L, Porteri E et al. Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol 1998; 32: 985-92.
  20. Varagic J, Trask A.J, Jessup J.A et al. New angiotensins. J Mol Med 2008; 86 (6): 663-71.
  21. Schmieder R.E, Hilgers K.F, Schlaich M.P, Schmidt B.M. Renin - angiotensin system and cardiovascular risk. Lancet 2007; 369 (9568): 1208-19.
  22. Weiss D, Sorescu D, Taylor W.R. Angiotensin II and atherosclerosis. Am J Cardiol 2001; 87 (8 A): 25C-32.
  23. Ferrario C.M, Strawn W.B. Role of the renin - angiotensin - aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98 (1): 121-8.
  24. Intengan H.D, Thibault G, Li J.S, Schiffrin E.L. Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats: effects of angiotensin receptor antagonism and converting enzyme inhibition. Circulation 1999; 100: 2267-75.
  25. Schiffrin E.L, Park J.B, Intengan H.D, Touyz R.M. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653-9.
  26. Schiffrin E.L. Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 2002; 113: 409-18.
  27. Mathiassen O.N, Buus N.H, Larsen M.L et al. Small artery structure adapts to vasodilatation rather than to blood pressure during antihypertensive treatment. J Hypertens 2007; 25: 1027-34.
  28. Ferrario C.M, Strawn W.B. Targeting the RAAS for the treatment of atherosclerosis. Drug Discov Today Ther Strateg 2005; 2 (3): 221-9.
  29. Hammoud R.A, Vaccari C.S, Nagamia S.H, Khan B.V. Regulation of the renin - angiotensin system in coronary atherosclerosis: a review of the literature. Vasc Health Risk Manag 2007; 3 (6): 937-45.
  30. Brunner H.R. Clinical efficacy and tolerability of olmesartan. Clin Ther 2004; 26 (Suppl. A): A28-32.
  31. Neutel J.M, Kereiakes D.J. An olmesartan medoxomil - based treatment algorithm is effective in achieving 24-hour BP control in patients with type 2 diabetes mellitus, regardless of age, race, sex, or severity of hypertension: subgroup analysis of the BENIFICIARY study. Am J Cardiovasc Drugs 2010; 10 (5): 289-303.
  32. Oparil S, Pimenta E. Efficacy of an olmesartan medoxomil - based treatment algorithm in patients stratified by age, race, or sex. J Clin Hypertens (Greenwich) 2010; 12 (1): 3-13.
  33. Zaman A.K, Fujii S, Goto D et al. Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity. J Mol Cell Cardiol 2004; 37 (2): 525-35.
  34. Naya M, Tsukamoto T, Morita K et al. J Am Coll Cardiol 2007; 50 (12): 1144-9.
  35. Smith R.D, Yokoyama H, Averill D.B et al. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics. Am J Cardiovasc Drugs 2006; 6: 335-42.
  36. Heagerty A.M. Predicting hypertension complications from small artery structure. J Hypertens 2007; 25: 939-40.
  37. Kyotani Y, Zhao J, Tomita S et al. Olmesartan inhibits angiotensin II - induced migration of vascular smooth muscle cells through Src and mitogen - activated protein kinase pathways. J Pharmacol Sci 2010; 113 (2): 161-8.
  38. Miyazaki M, Takai S. Anti - atherosclerotic efficacy of Olmesartan. J Human Hypertens 2002; 16 (Suppl. 2): S7-S12.
  39. Ferrario C.M. Use of angiotensin II receptor blockers in animal models of atherosclerosis. Am J Hypertens 2002; 15 (1 pt 2): 9S-13S.
  40. Takai S, Jin D, Sakaguchi M et al. The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high - cholesterol diet. J Hypertens 2005; 23 (10): 1879-86.
  41. Hirohata A, Yamamoto K, Miyoshi T et al. Impact of olmesartan on progression of coronary atherosclerosis: a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of olmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. JACC 2010; 55 (10): 976-82.
  42. Fliser D, Buchholz K, Haller H for the EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EU- TOPIA) Investigators. Anti - inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103-7.
  43. Stumpe K.O, Agabiti-Rosei E, Scholze J et al. Carotid intima - media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Therapeutic Advances in Cardiovascular Disease 2007; 1 (2): 97-106.
  44. Yao L, Kobori H, Rahman M et al. Olmesartan improves endothelin - induced hypertension and oxidative stress in rats. Hypertens Res 2004; 27 (7): 493-500.
  45. Fliser D, Wagner K.K, Loos A et al. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16: 1135-40.
  46. Blake G.J, Rifai N, Buring J.E et al. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003; 108: 2993-9.
  47. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-9.
  48. Nakayama S, Watada H, Mita T et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early - stage type-2 diabetics with hypertension. Hypertens Res 2008; 31 (1): 7-13.
  49. Koike H, Sada T, Mizuno M. In vitro and in vivo pharmacology of Olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. J Hypertens 2001; 19 (S1): S3-S14.
  50. Yoshida J, Yamamoto K, Mano T et al. AT1 Receptor Blocker Added to ACE Inhibitor Provides Benefits at Advanced Stage of Hypertensive Diastolic Heart Failure. Hypertension 2004; 43: 686-91.
  51. Jia N, Okamoto H, Shimizu T et al. A Newly Developed Angiotensin II Type 1 Receptor Antagonist, CS866, Promotes Regression of Cardiac Hypertrophy by Reducing Integrin b1 Expression. Hypertens Res 2003; 26: 737-42.
  52. Sanada S, Kitakaze M, Node K et al. Differential Subcellular Actions of ACE Inhibitors and AT1 Receptor Antagonists on Cardiac Remodeling Induced by Chronic Inhibition of NO Synthesis in Rats. Hypertension 2001; 38: 404-11.
  53. Takemoto M, Egashira K, Tomita H et al. Chronic Angiotensin- Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Blockade: Effects on Cardiovascular Remodeling in Rats Induced by the Long - term Blockade of Nitric Oxide Synthesis. Hypertension 1997; 30: 1621-7.
  54. Taniyama Y, Morishita R, Nakagami H et al. Potential Contribution of a Novel Antifibrotic Factor, Hepatocyte Growth Factor, to Prevention of Myocardial Fibrosis by Angiotensin II Blockade in Cardiomyopathic Hamsters. Circulation 2000; 102: 246-52.
  55. Ishiyama Y, Gallagher P.E, Averill D.B. Upregulation of Angiotensin- Converting Enzyme 2 аfter Myocardial Infarction by Blockade of Angiotensin II Receptors. Hypertension 2004; 43: 970-6.
  56. Nimata M, Kishimoto C, Yuan Z et al. Beneficial effects of Olmesartan, a novel angiotensin II receptor type 1 antagonist, upon acute autoimmune myocarditis. Mol Cell Biochem 2004; 259 (1-2): 217-22.
  57. Furuhashi M, Ura N, Takizawa H et al. Blockade of the renin - angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J of Hypertension 2004; 22: 1977-82.
  58. Higashiura K, Ura N, Takada T et al. The effects of an angiotensin - converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose - fed rats. Am J Hypertens 2000; 13 (3): 290-7.
  59. De Vinuesa S.G, Goicoechea M, Kanter J et al. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade. J Am Soc Nephrol 2006; 17: S206-12.
  60. Okada K, Hirano T, Ran J, Adachi M. Olmesartan medoxomil, an angiotensin II Receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructosefed rats. Hypertens Res 2004; 27 (4): 293-9.
  61. Ran J, Hirano T, Adachi M. Angiotensin II type 1 receptor blocker ameliorates Overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am J Physiol Endocrinol Metab 2004; 287 (2): E227-32.
  62. Simons W.R. Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: Olmesartan medoxomil compared with losartan, valsartan and irbesartan. Pharmacoeconomics 2003; 21 (1): 61-74.

© ООО "Эко-Вектор", 2015

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах